Kuorii to Exhibit at Sony Booth at CEATEC 2026, Showcase Microsurgery-Assistance Robot

prtimes.jp reported on September 15, 2026, “Kuorii to Exhibit at Sony Booth at CEATEC 2026, Showcase Microsurgery-Assistance Robot.” We have not been able to verify the primary information, so please refer to the original source for details.

Kuorii says it will carry on technology derived from a prototype Sony announced in 2024, connecting the results of medical robotics research with outside parties through an exhibition. Because the exhibit will be at Sony’s booth, it is important to stakeholders that it will be presented as part of a co-creation setting rather than as a company’s standalone research showcase.

The key point is that Kuorii will exhibit within Sony’s booth at CEATEC 2026, rather than exhibiting independently. The exhibit will feature a microsurgery-assistance robot, presenting a medical robotics concept within Sony’s co-creation framework. What is new is the explicit statement that Kuorii will carry on some of the technology derived from a prototype Sony announced in 2024. However, the announcement concerns participation in an exhibition; it does not establish that the conditions for mass production or clinical deployment have been met. Our related article, Sony’s new president to leverage strengths in physical AI, reported that Sony’s top executive had identified physical AI as an area of strength. This exhibit can be seen as reinforcing that statement at an exhibition, but what has actually been shown is technology and a concept, and its readiness as a product and stage of commercialization should be assessed separately. For Sony, presenting the results of medical robotics research under the name of an external partner is likely to connect its research assets with the context of co-creation. From an industry perspective, the significance lies less in competition over robot performance than in technology transfer and exhibition pathways in a field close to medical practice. As Kuorii carries forward the lineage of Sony’s prototype, the focus will be on how research and development, demonstrations and future commercialization are connected. Medical robots typically face outstanding issues around safety, suitability for surgical procedures and ease of use in clinical settings; this announcement reveals only what will be shown at the exhibition. The next points to confirm are which elements of the prototype’s technology will be carried forward, what will be presented as a physical system at the venue, and how the timing of clinical use and commercialization will be laid out.

In Japan, the deployment of medical robots depends on safety and suitability for clinical settings, making it important to see how far technology derived from Sony’s prototype will be developed in Kuorii’s exhibit. The transfer of technology originating in Sony’s research assets and its presentation by an external partner offer a case for considering how research results can be translated into real-world applications in Japan’s medical device and robotics sectors.